Sorafenib in advanced hepatocellular carcinoma - Test2 - elhamkhani - TriplyDB

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

http://www.wikidata.org/entity/Q27861075

about

Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adults Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin The transcription factor LSF: a novel oncogene for hepatocellular carcinoma Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma MicroRNA expression, survival, and response to interferon in liver cancer Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Transarterial radioembolization for hepatocellular carcinoma: a review Hepatocellular carcinoma in elderly patients: challenges and solutions Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis New advances in targeted gastric cancer treatment Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection How to Improve Therapeutic Ratio in Radiotherapy of HCC Progress in systemic therapy of advanced hepatocellular carcinoma Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments Pleiotropic effects of statins in the diseases of the liver Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Diabetes mellitus and metformin in hepatocellular carcinoma Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments miR-181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New Modulation of Autophagy by Sorafenib: Effects on Treatment Response Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy New advances in hepatocellular carcinoma A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016 Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells Development and novel therapeutics in hepatocellular carcinoma: a review Selective use of sorafenib in the treatment of thyroid cancer Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play Hepatocellular carcinoma: Where are we?Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib

P2860

Q21245706-6A3585D6-E7BE-4BC0-8984-E7BC3E16FD13 Q24187730-A594F181-AF14-46DC-9EFA-4BC8075EF0C1 Q24201669-54116865-A4A9-408C-8994-E713941BA73C Q24292953-E49E0CDA-8685-4189-AA0A-4895975483D9 Q24613885-AC79E304-A9D4-4FBF-9AEE-4E1C7900AE3F Q24616631-F01496EB-3047-4190-8A5F-5D325A66923C Q24619987-B091DF77-AE31-461C-8304-147094C85BCD Q24635267-B9E9EF11-A986-41F4-B1B1-050CDB6F2493 Q24647241-ED4B76B1-FAC3-412F-B673-0876415F38EF Q24647547-18C2E01A-1462-47FD-AB3E-B020430669C8 Q24655048-D1144F7C-1EA9-4D88-A8C7-7C590B4D7856 Q24657761-7F250BA9-40C2-43D6-942F-E51CB6743899 Q26738273-5D1860A7-8D40-4D0B-8CF8-9F0FB7CE6150 Q26738274-7D8F4775-BF87-42F4-9328-054BA7A2FEBB Q26738293-EA897FE9-4413-49B5-96FD-ECE5E204687F Q26738533-AC816BF3-163B-445D-ADDA-009188F0FDBB Q26738548-A41B42F0-1ED9-4344-AD0C-70C930953640 Q26738860-5ECB5202-E01A-443C-8493-0BE4F1929965 Q26738862-57148D12-F245-48B5-9DDC-C27BB1DFD39F Q26740217-CCB82716-01ED-42F2-ADA2-A51899B7A110 Q26740315-8305DBF1-3487-4C92-AB62-39B178BCA4E3 Q26741176-7672988D-6EDE-4205-BC6E-91E41988CEBE Q26741201-716E1CB9-B30A-4451-8824-28DF1F4B3564 Q26741205-7E24820C-F89E-4F3B-96D2-C62A5FDCDA4B Q26743603-D8AC3C07-52C4-40E4-9C64-7B4A2B839968 Q26743666-D26A0ACA-2550-4810-B061-9824738895CF Q26744201-6B6837B1-F8A2-4DE7-9749-A810A3ED3D67 Q26744542-32FA7705-7D2E-462D-96F2-B351CA060F23 Q26745320-CF259AD1-A8CE-4A1A-9D5E-D7E54A8134F0 Q26745962-6115710C-AA81-4800-9918-7C5819229CCA Q26749329-A52DC80D-6D38-412D-95AF-98F13E8AD23A Q26752478-07D70BEB-D4BC-4A5D-BEE0-100F98FDEFA1 Q26752653-D1CAE954-40CD-4FCB-9CF1-F338DDCCEFA6 Q26752854-CA7FF8A3-FFF3-428E-8746-EE4EEAC25810 Q26752891-344CFD8F-FA6D-45F5-96E7-5C3FBC168D2D Q26753089-43C2793F-CDB5-41CE-AB21-D42075D79B72 Q26764892-EC138D49-FA04-48BC-8729-65478FCEF3D3 Q26764911-08E63C0A-11D7-418F-8B98-2D7B9A33E78A Q26765182-B07229F9-E7F2-4ADB-83EB-66FFCF10647A Q26765210-28A8D4D8-AEDF-47F9-BAF9-5BD1E05EA2C1

P2860

Sorafenib in advanced hepatocellular carcinoma

http://www.wikidata.org/entity/Q27861075

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Sorafenib in advanced hepatocellular carcinoma

@ast

Sorafenib in advanced hepatocellular carcinoma

@en

Sorafenib in advanced hepatocellular carcinoma

@nl

type

label

Sorafenib in advanced hepatocellular carcinoma

@ast

Sorafenib in advanced hepatocellular carcinoma

@en

Sorafenib in advanced hepatocellular carcinoma

@nl

prefLabel

Sorafenib in advanced hepatocellular carcinoma

@ast

Sorafenib in advanced hepatocellular carcinoma

@en

Sorafenib in advanced hepatocellular carcinoma

@nl

P1433

Q27861075-E23B3610-219F-46E6-9A45-E60F8DA45A5C

P1476

Q27861075-A113AB6A-B085-400F-9E8D-179A12538EA1

P2093

Q27861075-12C5E28D-A303-422E-8589-941255BF237E

Q27861075-1319097B-036F-4570-A259-EF10F3C13987

Q27861075-1C5E0B9B-8786-4F77-B1C1-DED0FF0EED9F

Q27861075-4EC096D7-BD26-4986-A1CC-DBC8CF37A0D1

Q27861075-5B906F4F-C09F-49E6-8686-798DB2918B2D

Q27861075-643F9F0A-CCCB-4C8E-AF76-C9B8C56A8016

Q27861075-740B0E93-FD57-4A39-BBB7-E5289F43B0EF

Q27861075-7D938954-AD01-4142-80A0-6BDDE7274725

Q27861075-A5B1E0AE-B770-40B1-AB73-90C977EB82A0

Q27861075-B160B18D-C59C-4ECF-BBE5-69A4DDE1710E

P304

Q27861075-2C5C34CD-9D7B-4F6B-9B06-3B772CE0C91D

P31

Q27861075-3EC0F32F-F429-4A17-A26B-26E07C9A4C72

P3181

Q27861075-7F8C9BB0-C483-4AD4-A654-E42947C5661C

P356

Q27861075-C27DABE7-0E0C-47A9-96B5-66B448F0802D

P407

Q27861075-A17EB0AD-E708-4DE4-B87E-64404CBDD0DA

P433

Q27861075-06640A56-CE82-482A-A49C-C5470F538C81

P478

Q27861075-621008B6-0EF6-4343-859D-0E3ACDFEE071

P50

Q27861075-13016412-58F8-435E-8E10-C2E2DF068BEC

Q27861075-A023E5A5-2DE7-4800-9B9B-D7C6136064ED

Q27861075-A0447D6A-44F6-4E02-B67A-00060DD1677E

Q27861075-A9B04660-C80D-44C7-98A2-69E1BB7F4898

Q27861075-AFCE78D2-0563-47CB-BFF8-51D4F95D86AD

Q27861075-E852406E-1F18-41BD-8654-ED14473DC2A2

P577

Q27861075-B23F9B81-83EF-456A-A202-B45BF6029FEA

P698

Q27861075-1E20FB36-D21A-4487-89CF-4304B560EB8B

P3181

P356

P1433

The New England Journal of Medicine

P1476

Sorafenib in advanced hepatocellular carcinoma

@en

P2093

Andre Cosme de Oliveira

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Dimitris Voliotis

http://www.w3.org/2001/XMLSchema#string

Edward Gane

http://www.w3.org/2001/XMLSchema#string

Ivan Borbath

http://www.w3.org/2001/XMLSchema#string

Jean-François Seitz

http://www.w3.org/2001/XMLSchema#string

Jean-Frédéric Blanc

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Raoul

http://www.w3.org/2001/XMLSchema#string

Luigi Bolondi

http://www.w3.org/2001/XMLSchema#string

Marius Moscovici

http://www.w3.org/2001/XMLSchema#string

P304

378-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

118786

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0708857

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Dieter Häussinger

Alejandro Forner

Josep M. Llovet

P577

2008-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18650514

http://www.w3.org/2001/XMLSchema#string